Literature DB >> 33752634

Hazardous alcohol use is associated with greater pain interference and prescription opioid misuse among persons living with HIV and chronic pain.

Belle Ngo1, Jane M Liebschutz2, Debbie M Cheng3,4, Jonathan A Colasanti5, Jessica S Merlin2, Wendy S Armstrong5, Leah S Forman6, Marlene C Lira4, Jeffrey H Samet4,7,8, Carlos Del Rio5,9, Judith I Tsui10.   

Abstract

BACKGROUND: Alcohol use is common among persons living with HIV (PLWH), who often experience chronic pain, yet its impact on pain and opioid misuse is not fully characterized.
METHODS: We assessed associations between hazardous alcohol use and pain interference, defined as the self-reported impact of pain on daily living, pain severity, and risk for opioid misuse among PLWH who were on long-term opioid therapy (LTOT). A cohort was recruited as part of the "Targeting Effective Analgesia in Clinics for HIV" (TEACH) study, a randomized controlled trial to improve LTOT in HIV clinics. The Alcohol Use Disorders Test (AUDIT), Brief Pain Inventory (BPI) and the Current Opioid Misuse Measure (COMM) were administered at both baseline and 12-months. Linear mixed and generalized estimating equation models, incorporating data from both time points, evaluated associations between hazardous alcohol use (AUDIT ≥8) and: pain interference (0-10), pain severity (0-10), and opioid misuse risk (COMM ≥13), adjusting for age, gender, depressive symptoms, use of non-alcohol substances, time-point, and study-arm.
RESULTS: The sample was comprised of 166 participants, of which 31 (19%) reported hazardous alcohol use. The majority were male (65%), black (72%), and the mean age was 54 (range: 29-77). Hazardous alcohol use was significantly associated with higher pain interference (adjusted mean difference [AMD]: 1.02; 95% CI: 0.08, 1.96) and higher odds of opioid misuse risk (AOR: 3.73, 95% CI: 1.88-7.39), but not pain severity (AMD: 0.47, 95% CI: - 0.35, 1.29).
CONCLUSIONS: Hazardous alcohol use was associated with greater functional impairment in daily living from their pain and higher odds for prescription opioid misuse in this study of PLWH on LTOT. Providers should be attentive to alcohol use among PLWH who are prescribed opioids given associations with pain and opioid misuse. TRIAL REGISTRATION: ClinicalTrials.gov NCT02564341 (Intervention, September 30, 2015) and NCT02525731 (Patient Cohort, August 17, 2015). Both prospectively registered.

Entities:  

Keywords:  Alcohol; HIV; Opioids; Pain; Substance use

Mesh:

Substances:

Year:  2021        PMID: 33752634      PMCID: PMC7986380          DOI: 10.1186/s12889-021-10566-6

Source DB:  PubMed          Journal:  BMC Public Health        ISSN: 1471-2458            Impact factor:   3.295


  55 in total

1.  Drinking to cope, emotional distress and alcohol use and abuse: a ten-year model.

Authors:  C J Holahan; R H Moos; C K Holahan; R C Cronkite; P K Randall
Journal:  J Stud Alcohol       Date:  2001-03

2.  The relationship between past-year drinking behaviors and nonmedical use of prescription drugs: prevalence of co-occurrence in a national sample.

Authors:  Sean Esteban McCabe; James A Cranford; Carol J Boyd
Journal:  Drug Alcohol Depend       Date:  2006-04-18       Impact factor: 4.492

3.  Systematic review of prevalence, correlates, and treatment outcomes for chronic non-cancer pain in patients with comorbid substance use disorder.

Authors:  Benjamin J Morasco; Susan Gritzner; Lynsey Lewis; Robert Oldham; Dennis C Turk; Steven K Dobscha
Journal:  Pain       Date:  2010-12-23       Impact factor: 6.961

Review 4.  Prescription drug abuse: from epidemiology to public policy.

Authors:  R Kathryn McHugh; Suzanne Nielsen; Roger D Weiss
Journal:  J Subst Abuse Treat       Date:  2014-08-28

5.  Pain as a global public health priority.

Authors:  Daniel S Goldberg; Summer J McGee
Journal:  BMC Public Health       Date:  2011-10-06       Impact factor: 3.295

6.  A Multicomponent Intervention to Improve Primary Care Provider Adherence to Chronic Opioid Therapy Guidelines and Reduce Opioid Misuse: A Cluster Randomized Controlled Trial Protocol.

Authors:  Karen E Lasser; Christopher Shanahan; Victoria Parker; Donna Beers; Ziming Xuan; Orlaith Heymann; Allison Lange; Jane M Liebschutz
Journal:  J Subst Abuse Treat       Date:  2015-07-15

7.  Improving the Delivery of Chronic Opioid Therapy among People Living with HIV: A Cluster Randomized Clinical Trial.

Authors:  Jeffrey H Samet; Judith I Tsui; Debbie M Cheng; Jane M Liebschutz; Marlene C Lira; Alexander Y Walley; Jonathan A Colasanti; Leah S Forman; Christin Root; Christopher W Shanahan; Margaret M Sullivan; Carly L Bridden; Catherine Abrams; Catherine Harris; Kishna Outlaw; Wendy S Armstrong; Carlos Del Rio
Journal:  Clin Infect Dis       Date:  2020-07-22       Impact factor: 9.079

8.  Daily factors driving daily substance use and chronic pain among older adults with HIV: An exploratory study using ecological momentary assessment.

Authors:  Alexis Kuerbis; M Carrington Reid; Jordan E Lake; Suzette Glasner-Edwards; Jessica Jenkins; Diana Liao; Jury Candelario; Alison A Moore
Journal:  Alcohol       Date:  2018-10-09       Impact factor: 2.405

9.  Predictors of opioid misuse in patients with chronic pain: a prospective cohort study.

Authors:  Timothy J Ives; Paul R Chelminski; Catherine A Hammett-Stabler; Robert M Malone; J Stephen Perhac; Nicholas M Potisek; Betsy Bryant Shilliday; Darren A DeWalt; Michael P Pignone
Journal:  BMC Health Serv Res       Date:  2006-04-04       Impact factor: 2.655

10.  Psychosocial factors associated with persistent pain in people with HIV: a systematic review with meta-analysis.

Authors:  Whitney Scott; Chinar Arkuter; Kitty Kioskli; Harriet Kemp; Lance M McCracken; Andrew S C Rice; Amanda C de C Williams
Journal:  Pain       Date:  2018-12       Impact factor: 6.961

View more
  1 in total

1.  Risky alcohol use among patients dispensed opioid medications: A clinical community pharmacy study.

Authors:  Gerald Cochran; Elizabeth Charron; Jennifer L Brown; Alina Cernasev; Kenneth C Hohmeier; T John Winhusen
Journal:  Drug Alcohol Depend       Date:  2022-03-16       Impact factor: 4.852

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.